Acepodia Reports the US FDA Clearance of IND Application for ACE2016 to Treat Solid Tumors
Shots:
- The company received the US FDA’s clearance on the IND application submitted for ACE2016 based on the preclinical results depicting the effects of ACE2016 in solid tumor models
- Following the US FDA’s clearance, Acepodia expects to initiate a P-I FIH trial evaluation the safety, efficacy, tolerability & PD of ACE2016 in patients with locally advanced or metastatic EGFR-expressing solid tumors. The first patient dosing is expected by H2’24
- ACE2016 is an allogenic γδ2 T cell therapy candidate developed using the company’s proprietary ACC platform to target EGFR-expressing solid tumors through antibody conjugated γδ2 T cells
Ref: PR Newswire | Image: Acepodia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
